{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:19:10Z","timestamp":1740136750816,"version":"3.37.3"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Assessment of surgical outcome in acromegaly is typically recommended at 3 to 6 months following surgery. The purpose of this study was to determine if insulin-like growth factor 1 (IGF-1) concentrations at 6 weeks were equally predictive of surgical outcomes compared with IGF-1 concentrations at 3 to 6 months postoperatively applying newer IGF-1 assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective review of patients with newly diagnosed acromegaly who had surgery between 2013 and 2020 and had postoperative IGF-1 measured by 6 weeks and 3 to 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At 6 weeks, 20 (35%) of the total 57 had normal IGF-1 and became abnormal in 1 at 3 to 6 months, whereas 37 (65%) of 57 had abnormal IGF-1 concentrations at 6 weeks, which normalized in 1 patient by 3 to 6 months. In patients who changed clinical status, IGF-1 at 6 weeks was within \u00b10.1-fold of normal. Although a difference was seen between median IGF-1 concentrations (286 vs 267 ng\/mL, P = .009) at 6 weeks and 3 to 6 months, the mean reduction was small (\u201319.9 ng\/mL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compared with 3 to 6 months, use of IGF-1 at 6 weeks was associated with a change in clinical status in 3.5% of patients. Therefore, in most patients, IGF-1 at 6 weeks can be used to assess clinical outcome via newer assays.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqab168","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:21:22Z","timestamp":1631100082000},"page":"595-601","source":"Crossref","is-referenced-by-count":0,"title":["Insulin-Like Growth Factor 1 in the Early Postoperative Assessment of Acromegaly"],"prefix":"10.1093","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5091-9582","authenticated-orcid":false,"given":"Diane","family":"Donegan","sequence":"first","affiliation":[{"name":"Department of Endocrinology Diabetes and Metabolism, Indiana University School of Medicine , Indianapolis, IN , USA"},{"name":"Department of Endocrinology, Diabetes and Metabolism, Mayo College of Medicine , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Algeciras-Schimnich","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Ashrafzadeh-Kian","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Erickson","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Mayo College of Medicine , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"2023020617105731500_CIT0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11102-017-0789-7","article-title":"The genetic background of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary."},{"key":"2023020617105731500_CIT0002","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0003","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0004","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJM197911223012102","article-title":"Evaluation of acromegaly by radioimmunoassay of somatomedin-C","volume":"301","author":"Clemmons","year":"1979","journal-title":"N Engl J Med."},{"key":"2023020617105731500_CIT0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"key":"2023020617105731500_CIT0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-017-0849-z","article-title":"Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study","volume":"21","author":"Bonert","year":"2018","journal-title":"Pituitary."},{"key":"2023020617105731500_CIT0007","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1210\/jc.2005-0901","article-title":"Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels","volume":"90","author":"Feelders","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly","volume":"94","author":"Carmichael","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0009","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1210\/jc.2007-2104","article-title":"Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly","volume":"93","author":"Alexopoulou","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0010","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/jcem.86.9.7819","article-title":"Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria","volume":"86","author":"Kreutzer","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0011","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1373\/clinchem.2016.262592","article-title":"Decrease of serum IGF-I following transsphenoidal pituitary surgery for acromegaly","volume":"63","author":"Yu","year":"2017","journal-title":"Clin Chem."},{"key":"2023020617105731500_CIT0012","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1507\/endocrj.EJ11-0146","article-title":"Gradual declination of IGF-1 over a year after transsphenoidal adenomectomy of GH producing pituitary adenomas","volume":"58","author":"Fujio","year":"2011","journal-title":"Endocr J."},{"key":"2023020617105731500_CIT0013","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1227\/01.neu.0000431480.87160.84","article-title":"Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone\u2013secreting pituitary adenoma","volume":"73","author":"Shin","year":"2013","journal-title":"Neurosurgery."},{"key":"2023020617105731500_CIT0014","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol."},{"key":"2023020617105731500_CIT0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11102-012-0447-z","article-title":"Diagnostic delay is associated with psychosocial impairment in acromegaly","volume":"16","author":"Siegel","year":"2013","journal-title":"Pituitary."},{"key":"2023020617105731500_CIT0016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2265.2011.04019.x","article-title":"The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly","volume":"75","author":"Jayasena","year":"2011","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2023020617105731500_CIT0017","doi-asserted-by":"crossref","DOI":"10.3390\/jpm7030007","article-title":"Empowering Mayo Clinic individualized medicine with genomic data warehousing","volume":"7","author":"Horton","year":"2017","journal-title":"J Pers Med."},{"key":"2023020617105731500_CIT0018","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1373\/clinchem.2014.234799","article-title":"Detection of IGF-1 protein variants by use of LC-MS with high-resolution accurate mass in routine clinical analysis","volume":"61","author":"Hines","year":"2015","journal-title":"Clin Chem."},{"key":"2023020617105731500_CIT0019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4158\/EP-2018-0040","article-title":"Necessity of multimodal treatment of acromegaly and outcomes","volume":"24","author":"Donegan","year":"2018","journal-title":"Endocr Pract."},{"key":"2023020617105731500_CIT0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.wneu.2016.08.088","article-title":"Cavernous sinus invasion in pituitary adenomas: systematic review and pooled data meta-analysis of radiologic criteria and comparison of endoscopic and microscopic surgery","volume":"96","author":"Dhandapani","year":"2016","journal-title":"World Neurosurg."},{"key":"2023020617105731500_CIT0021","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg."},{"key":"2023020617105731500_CIT0022","first-page":"216","article-title":"Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol","volume":"77","author":"Holl","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0023","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2265.1990.tb00920.x","article-title":"The application of deconvolution analysis to elucidate the pulsatile nature of growth hormone secretion using a variable half-life of growth hormone","volume":"32","author":"Hindmarsh","year":"1990","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2023020617105731500_CIT0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/jcem-68-3-535","article-title":"Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin","volume":"68","author":"Faria","year":"1989","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0025","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3171\/2013.8.JNS13224","article-title":"Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria","volume":"119","author":"Hazer","year":"2013","journal-title":"J Neurosurg."},{"key":"2023020617105731500_CIT0026","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00701-014-2098-5","article-title":"Transsphenoidal surgery for acromegaly: predicting remission with early postoperative growth hormone assays","volume":"156","author":"Sarkar","year":"2014","journal-title":"Acta Neurochir (Wien)."},{"key":"2023020617105731500_CIT0027","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/0028-3886.177622","article-title":"Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?","volume":"64","author":"Dutta","year":"2016","journal-title":"Neurol India."},{"key":"2023020617105731500_CIT0028","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1227\/NEU.0b013e31823f5c16","article-title":"Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly","volume":"70","author":"Kim","year":"2012","journal-title":"Neurosurgery."},{"journal-title":"World Neurosurg.","article-title":"Surgical results and predictors of initial and delayed remission for growth hormone\u2013secreting pituitary adenomas using the 2010 consensus criteria in 162 patients from a single center [published online November 27, 2018]","author":"Shen","key":"2023020617105731500_CIT0029"},{"key":"2023020617105731500_CIT0030","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0031","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11102-011-0369-1","article-title":"Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na\u00efve to medical therapy and radiation: what to follow, GH or IGF-1 values?","volume":"15","author":"Brzana","year":"2012","journal-title":"Pituitary."},{"key":"2023020617105731500_CIT0032","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ghir.2008.02.001","article-title":"Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR","volume":"18","author":"Machado","year":"2008","journal-title":"Growth Horm IGF Res."},{"key":"2023020617105731500_CIT0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2265.2006.02430.x","article-title":"Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status","volume":"64","author":"Espinosa-de-Los-Monteros","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2023020617105731500_CIT0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ghir.2018.03.002","article-title":"Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly","volume":"41","author":"Rotermund","year":"2018","journal-title":"Growth Horm IGF Res."},{"key":"2023020617105731500_CIT0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-10-0744","article-title":"Limited utility of oral glucose tolerance test in biochemically active acromegaly","volume":"164","author":"Ribeiro-Oliveira","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"2023020617105731500_CIT0036","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11102-016-0735-0","article-title":"\u201cMicromegaly\u201d: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era","volume":"19","author":"Butz","year":"2016","journal-title":"Pituitary."},{"key":"2023020617105731500_CIT0037","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1210\/jc.2018-01113","article-title":"Prevalence, clinical and biochemical spectrum, and treatment outcome of acromegaly with normal basal GH at diagnosis","volume":"103","author":"Espinosa de Los Monteros","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"2023020617105731500_CIT0038","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1507\/endocrj.52.125","article-title":"Slow postoperative decline in blood concentration of insulin-like growth factor-1 (IGF-1) in acromegalic patients","volume":"52","author":"Arita","year":"2005","journal-title":"Endocr J."},{"key":"2023020617105731500_CIT0039","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine."},{"key":"2023020617105731500_CIT0040","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3171\/2016.8.JNS161123","article-title":"Correlation between GH and IGF-1 during treatment for acromegaly","volume":"126","author":"Oldfield","year":"2017","journal-title":"J Neurosurg."},{"key":"2023020617105731500_CIT0041","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ghir.2005.05.002","article-title":"Rh\/IGF-I\/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose","volume":"15","author":"Clemmons","year":"2005","journal-title":"Growth Horm Igf Res."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/157\/4\/595\/49103158\/aqab168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/157\/4\/595\/49103158\/aqab168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:11:46Z","timestamp":1675703506000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/157\/4\/595\/6403146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqab168","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"type":"print","value":"0002-9173"},{"type":"electronic","value":"1943-7722"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,10,19]]}}}